International Urology and Nephrology

, Volume 51, Issue 8, pp 1335–1342 | Cite as

Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience

  • Wen-Hsin Tseng
  • Chien-Liang LiuEmail author
  • Steven K. Huang
  • Alex Chien-Hwa Liao
  • Jinn-Rung Kuo
  • Shun-Hsing Hun
  • Chun-Hao Chen
  • Chia-Cheng Su
  • Jhih-Cheng Wang
  • Kau-Han Lee
  • Kun-Hung Shen
  • Chien-Feng Li
Urology - Original Paper



In recent years, second-look transurethral resection of bladder tumors (TURBT) has been recommended for patients with stage T1 bladder cancer after the initial TURBT for restaging and deciding the subsequent treatment. However, we believe that second-look TURBT has therapeutic benefits, such as low incidence of recurrence and progression. Therefore, we compare the differences in long-term outcome between patients who did and did not accept second-look TURBT for stage T1 bladder cancer.


We assessed 504 patients diagnosed with urothelial carcinoma who underwent initial TURBT between January 2012 and December 2016 at a single medical center; of these patients, 177 were diagnosed with T1 bladder cancer during the initial TURBT, and we excluded no muscle from the specimen in the initial TURBT. The patients were categorized into groups 1 and 2 based on the acceptance of second-look TURBT, which was performed within 4–14 weeks after the initial TURBT. Group 1 underwent second-look TURBT, but group 2 did not. Both groups were followed-up for recurrence-free survival (RFS) and progression-free survival (PFS), and the risk factors for recurrence and progression were analyzed.


In total, 93 (52.5%) patients in group 1 underwent second-look TURBT, and 84 (47.5%) in group 2 did not. The 2-year RFS rates were 74.6% and 60.0% and the PFS rates were 91.2% and 87.5% in groups 1 and 2, respectively.


This study demonstrated higher recurrence-free and progression-free survival rates for patients who underwent second-look TURBT. This result emphasizes the importance of second-look TURBT in stage T1 bladder cancer not only for restaging but also for therapeutic benefit.


Second-look TURBT Transurethral resection of bladder tumors T1 bladder cancer Therapeutic benefit 



The author wishes to acknowledge to Dr. Tseng, Chien-Chang, Ying-Hsia, Shen, Yu-Ping, Huang for guidance.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Ethics approval

All procedures involving human participants were performed in accordance with the ethical standards of the institutional research committee and the 1964 Declaration of Helsinki.


  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRefGoogle Scholar
  2. 2.
    Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241CrossRefPubMedGoogle Scholar
  3. 3.
    Richards KA, Smith ND, Steinberg GD (2014) The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies. J Urol 191:1655–1664CrossRefPubMedGoogle Scholar
  4. 4.
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Bladder Cancer. 2019 Version 1. Accessed 20 Dec 2018
  5. 5.
    Babjuk M, Böhle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461CrossRefPubMedGoogle Scholar
  6. 6.
    Cumberbatch MG, Foerster B, Catto JW et al (2018) Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol 73:925–933CrossRefPubMedGoogle Scholar
  7. 7.
    Naselli A, Hurle R, Paparella S et al (2017) Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 4:558–567CrossRefPubMedGoogle Scholar
  8. 8.
    Dobruch J, Borówka A, Herr HW (2014) Clinical value of transurethral second resection of bladder tumor: systematic review. Urology 84:881–885CrossRefPubMedGoogle Scholar
  9. 9.
    Kim W, Song C, Park S et al (2012) Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor. J Endourol 26:1059–1064CrossRefPubMedGoogle Scholar
  10. 10.
    Koie T, Ohyama C, Hosogoe S et al (2015) Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. Int Urol Nephrol 47:1509–1514CrossRefPubMedGoogle Scholar
  11. 11.
    Han KS, Joung JY, Cho KS et al (2008) Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol 22:2699–2704CrossRefPubMedGoogle Scholar
  12. 12.
    Schwaibold HE, Sivalingam S, May F et al (2006) The value of a second transurethral resection for T1 bladder cancer. BJU Int 97:1199–1201CrossRefPubMedGoogle Scholar
  13. 13.
    Divrik T, Yildirim Ü, Şkin Eroğlu A et al (2006) Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 175:1258–1261CrossRefPubMedGoogle Scholar
  14. 14.
    Divrik RT, Şahin AF, Yildirim Ü et al (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 58:185–190CrossRefPubMedGoogle Scholar
  15. 15.
    Hashine K, Ide T, Nakashima T et al (2016) Results of second transurethral resection for high-grade T1 bladder cancer. Urol Ann 8:10–15CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sfakianos JP, Kim PH, Hakimi AA et al (2014) The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette–Guérin. J Urol 191:341–345CrossRefPubMedGoogle Scholar
  17. 17.
    Herr HW, Dalbagni G, Donat SM (2011) Bacillus Calmette–Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol 60:32–36CrossRefPubMedGoogle Scholar
  18. 18.
    Grossman HB, Stenzl A, Fradet Y et al (2012) Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 188:58–62CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Naito S, Algaba F, Babjuk M et al (2016) The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol 70:506–515CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang J, Wang L, Mao S et al (2018) Transurethral en bloc resection with bipolar button electrode for non-muscleinvasive bladder cancer. Int Urol Nephrol 50:619–623CrossRefPubMedGoogle Scholar
  21. 21.
    Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477CrossRefPubMedGoogle Scholar
  22. 22.
    Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette–Guerin: the CUETO scoring model. J Urol 182:2195–2203CrossRefPubMedGoogle Scholar
  23. 23.
    Li HM, Azhati B, Rexiati M et al (2017) Impact of smoking status and cumulative smoking exposure on tumor recurrence of non-muscle-invasive bladder cancer. Int Urol Nephrol 49:69–76CrossRefPubMedGoogle Scholar
  24. 24.
    Xu T, Zhu Z, Wang X et al (2015) Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer. Int Urol Nephrol 47:1135–1141CrossRefPubMedGoogle Scholar
  25. 25.
    Mashni J, Godoy G, Haarer C et al (2014) Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. Int Urol Nephrol 46:1699–1705CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Teoh JY, Chan ES, Yip SY et al (2017) Comparison of detrusor muscle sampling rate in monopolar and bipolar transurethral resection of bladder tumor: a randomized trial. Ann Surg Oncol 24:1428–1434CrossRefPubMedGoogle Scholar
  27. 27.
    Del Rosso A, Pace G, Masciovecchio S et al (2013) Plasmakinetic bipolar versus monopolar transurethral resection of non-muscle invasive bladder cancer: a single center randomized controlled trial. Int J Urol 20:399–403CrossRefPubMedGoogle Scholar
  28. 28.
    Venkatramani V, Panda A, Manojkumar R et al (2014) Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. J Urol 191:1703–1707CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  • Wen-Hsin Tseng
    • 1
  • Chien-Liang Liu
    • 1
    • 2
    Email author
  • Steven K. Huang
    • 1
  • Alex Chien-Hwa Liao
    • 1
  • Jinn-Rung Kuo
    • 3
  • Shun-Hsing Hun
    • 4
  • Chun-Hao Chen
    • 1
  • Chia-Cheng Su
    • 1
  • Jhih-Cheng Wang
    • 1
  • Kau-Han Lee
    • 1
  • Kun-Hung Shen
    • 1
  • Chien-Feng Li
    • 5
  1. 1.Division of Urology, Department of SurgeryChi Mei Medical CenterTainanTaiwan
  2. 2.Division of Uro-Oncology, Department of SurgeryChi Mei Medical CenterTainanTaiwan
  3. 3.Division of Neurosurgery, Department of SurgeryChi Mei Medical CenterTainanTaiwan
  4. 4.Division of Urology, Department of SurgeryChi Mei HospitalTainanTaiwan
  5. 5.Department of PathologyChi Mei Medical CenterTainanTaiwan

Personalised recommendations